AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05415956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise therapy
Description: Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
Study NCT04946825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit electronic cigarettes
Description: Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
Study NCT05228249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood ASCT
Study NCT05228249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT05228249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT05228249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05228249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given IV
Study NCT05228249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT06502951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling,Thrust Manipulation
Description: HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
Study NCT06502951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise,Non-thrust Mobilization
Description: Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
Study NCT05522634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJAOA101
Description: Once enrolled, participants will be administrated TJAOA101
Study NCT05530850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Corrective Exercise Program
Description: A holistic approach corrective exercise program including corrective exercises and postural perception training,
Study NCT05530850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic exercise program
Description: Thoracic region focused exercise program
Study NCT04946825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continue electronic cigarettes
Description: Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
Study NCT05529069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by PO
Study NCT05529069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT04730167 — intervention group
Intervention type: OTHER
Intervention: Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.
Description: Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
Study NCT05177081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preemptive management using home BIA monitoring system
Description: Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
Study NCT06175390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET/CT
Description: Tumor assessments by 18F-FDG PET/CT (per PERCIST v1.0) and 68Ga-FAPI-46 PET/CT will be performed at: baseline and after the first 2 treatment cycles (between C2D15 and C3D1).
Study NCT06175390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor samples analysis
Description: Patients will undergo a mandatory biopsy of the primary tumor at baseline, after the first 2 treatment cycles and during the surgery. A lymph node biopsy will be performed at baseline if feasible in cohort A, and and in case of disease progression for cohort B (if clinically feasible).~In addition to the usual morphological and immunohistochemical (ER, PR, HER2+, CPS score, PD-L1 status with SP142 ...) analyses in the cohort A and cohort B , exploratory analyses will be performed.
Study NCT06175390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples analysis: Circulating Tumor DNA
Description: Blood samples will be collected at baseline. In addition for cohort A at cycles 2 and 3, within 21 days before surgery, 10 to 21 days after surgery and at cycle 8 after surgery. In addition for cohort B after the first 2 treatment cycles and in case of disease progression (if clinically feasible).
Study NCT06415734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: LF-rTMS of M1 contralateral to the brain lesion for 20 min, 1200 pulses, 120% RMT, treatment cycle of 5 days
Study NCT04738851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy Mirror task
Description: The protocol has 3 conditions:~* A virtual TM task (TMV~* A classic TM task (TMC)~* A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions.
Study NCT06329804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Handgrip Exercise Training (IHGT)
Description: Each IHGT session will consist of 4 x 2-minute contractions at 30% maximal voluntary contraction, with 2-minutes of rest in between, performed with the dominant hand. Training will be performed using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong).
Study NCT06329804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Handgrip Exercise Training (IHGT)
Description: Each IHGT session will consist of 4 x 2-minute contractions at 30% maximal voluntary contraction, with 2-minutes of rest in between, performed with the dominant hand. Training will be performed using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong).
Study NCT05406986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care bundle application
Description: The patients in the experimental group will be given care according to the current care bundle for 14 days
Study NCT06247592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater occipital nerve block
Description: Pulse Radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location at 42 degree, for 240 seconds.
Study NCT06247592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve pulse radiofrequency
Description: The greater occipital nerve will be blocked with 5 cc 2% prilocaine.
Study NCT05972083 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study NCT05972083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study NCT05219045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ohio RETAIN
Description: RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
Study NCT05601999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-060
Description: GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
Study NCT05601999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Metalyse
Description: Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
Study NCT05399628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter
Description: Participants will be assigned to perform the procedure with LISA catheter with a marked tip
Study NCT05399628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter
Description: Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
Study NCT05756673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study NCT05756673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study NCT05931562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Foods
Description: Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.
Study NCT05931562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fibre
Description: Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
Study NCT05931562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Diet
Description: Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.
Study NCT05931562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will recieve dietary education based on the Irish healthy food pyramid.
Study NCT06501300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-focused: Tuning in to Kids in School
Description: The aim of the TIKiS is to improve emotion coaching and reduce emotion dismissing in elementary school teachers through six x 90-minute group sessions.
Study NCT06432998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal massage
Description: The technique will be applied for approximately twenty minutes and will be carried out as follows: the vaginal dilator is introduced progressively using crescent-shaped movements. Once the dilator is fully inserted, movements will be made from bottom to top and from one side to the other, and then continue with the crescent-shaped movements.
Study NCT06432998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The treatment will consist of the use of vaginal dilators according to the gold standard proposed in the literature. It will consist of introducing the same dilators as for the experimental group, with the same time schedule, but without massage, only introducing the dilator and keeping it in the vagina for 20 minutes.
Study NCT05756673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISTERINE ZERO Alcohol Mouthwash COOL MINT
Description: Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
Study NCT05756673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISTERINE COOL MINT Antiseptic Mouthwash
Description: Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
Study NCT05756673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TePe Original Interdental Brush
Description: Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
Study NCT05066334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous BM-MSC
Description: intradiscal injection of autologous bone marrow mesenchymal stromal cells
Study NCT05066334 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: local anaesthesia, no disc injection, no placebo injection
Study NCT04582812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training
Description: Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
Study NCT04582812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isolated inspiratory training
Description: Isolated high-intensity inspiratory muscle training during 8 weeks
Study NCT04801901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dTRA
Description: Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
Study NCT04801901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fTRA
Description: Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
Study NCT05725096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Computed Tomography Angiography
Description: Intervention strategies according to CCTA results
Study NCT05725096 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional cardiovascular risk stratification
Description: Intervention strategies according to traditional cardiovascular risk stratification based on Chinese guidelines for lipid management (2023)
Study NCT05627661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosensor
Description: Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
Study NCT05627661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosensor
Description: Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
Study NCT05878353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decontamination of the pocket with local doxycycline
Description: Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
Study NCT05878353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decontamination of the pocket with mechanical instrumentation
Description: Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
Study NCT05955326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovateltide
Description: Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
Study NCT05955326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
Study NCT03284437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Cognitive Training
Description: Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
Study NCT04882501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QUEASEEase aromatherapy quick tab
Description: Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
Study NCT04882501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
Study NCT04090723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI-CC with peer navigation
Description: Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
Study NCT05534087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX-FOLFIRI intensified chemotherapy
Description: (1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2
Study NCT05534087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX or CAPOX adjuvant chemotherapy
Description: 1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14
Study NCT06249893 — intervention group
Intervention type: OTHER
Intervention: Point-of-care vascular ultrasound
Description: Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
Study NCT04612790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Study NCT04612790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Study NCT06579040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monoplace Hyperbaric Chamber (Class III medical device)
Description: Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
Study NCT05758415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study NCT04693221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of VNS set of parameters based on the lowest PLI
Description: Vagal nerve stimulation according to PLI results.
Study NCT04693221 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EEG
Description: Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
Study NCT04693221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.